SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin - Quaterly Results

27 Oct 2021 Evaluate
The sales for the September 2021 quarter moved down to Rs. 28701.70 millions as compared to Rs. 30426.00 millions during the year-ago period.The Net Loss for the quarter ended September 2021 is Rs. -13291.20 millions as compared to Net Profit of Rs. 3604.30 millions of corresponding quarter ended September 2020Operating profit Margin for the quarter ended September 2021 slipped to -13242.70% as compared to 6230.70% of corresponding quarter ended September 2020


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 28701.70 30426.00 -5.67 61842.90 57376.80 7.78 110559.30 110256.60 0.27
Other Income 746.80 252.90 195.29 1263.60 593.00 113.09 1290.90 4751.90 -72.83
PBIDT -13242.70 6230.70 -312.54 -3347.20 12523.80 -126.73 21731.50 23828.00 -8.80
Interest 182.60 91.30 100.00 330.80 178.10 85.74 406.20 525.90 -22.76
PBDT -13425.30 6139.40 -318.67 -3678.00 12345.70 -129.79 21325.30 15710.00 35.74
Depreciation 1299.00 1256.00 3.42 2552.60 2507.40 1.80 5028.30 5187.50 -3.07
PBT -14724.30 4883.40 -401.52 -6230.60 9838.30 -163.33 16297.00 10522.50 54.88
TAX -1433.10 1279.10 -212.04 601.90 2598.20 -76.83 3710.80 3247.00 14.28
Deferred Tax 1760.30 -20.30 -8771.43 1729.70 -73.80 -2443.77 82.30 -373.50 -122.03
PAT -13291.20 3604.30 -468.76 -6832.50 7240.10 -194.37 12586.20 7275.50 72.99
Equity 908.10 906.50 0.18 908.10 906.50 0.18 907.40 906.00 0.15
PBIDTM(%) -46.14 20.48 -325.31 -5.41 21.83 -124.80 19.66 21.61 -9.05

Lupin Share Price

2476.10 77.40 (3.23%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: